Vertical-external-cavity surface-emitting lasers and quantum dot lasers

The use of cavity to manipulate photon emission of quantum dots (QDs) has been opening unprecedented opportunities for realizing quantum functional nanophotonic devices and also quantum information devices. In particular, in the field of semiconductor lasers, QDs were introduced as a superior alternative to quantum wells to suppress the temperature dependence of the threshold current in vertical-external-cavity surface-emitting lasers (VECSELs). In this work, a review of properties and development of semiconductor VECSEL devices and QD laser devices is given. Based on the features of VECSEL devices, the main emphasis is put on the recent development of technological approach on semiconductor QD VECSELs. Then, from the viewpoint of both single QD nanolaser and cavity quantum electrodynamics (QED), a single-QD-cavity system resulting from the strong coupling of QD cavity is presented. A difference of this review from the other existing works on semiconductor VECSEL devices is that we will cover both the fundamental aspects and technological approaches of QD VECSEL devices. And lastly, the presented review here has provided a deep insight into useful guideline for the development of QD VECSEL technology and future quantum functional nanophotonic devices and monolithic photonic integrated circuits (MPhICs).Comment: 21 pages, 4 figures. arXiv admin note: text overlap with arXiv:0904.369

A Virtual Testing Approach for Laminated Composites Based on Micromechanics

International audienceThe chapter deals with a crucial question for the design of composite structures: how can one predict the evolution of damage up to and including final fracture? Virtual testing, whose goal is to drastically reduce the huge number of industrial tests involved in current characterization procedures, constitutes one of today’s main industrial challenges. In this work, one revisits our multiscale modeling answer through its practical aspects. Some complements regarding identification, kinking, and crack initiation are also given. Finally, the current capabilities and limits of this approach are discussed, as well as the computational challenges that are inherent to “Virtual Structural Testing.

Ebola and Marburg Hemorrhagic Fevers: Neglected Tropical Diseases?

Ebola hemorrhagic fever (EHF) and Marburg hemorrhagic fever (MHF) are rare viral diseases, endemic to central Africa. The overall burden of EHF and MHF is small in comparison to the more common protozoan, helminth, and bacterial diseases typically referred to as neglected tropical diseases (NTDs). However, EHF and MHF outbreaks typically occur in resource-limited settings, and many aspects of these outbreaks are a direct consequence of impoverished conditions. We will discuss aspects of EHF and MHF disease, in comparison to the “classic” NTDs, and examine potential ways forward in the prevention and control of EHF and MHF in sub-Saharan Africa, as well as examine the potential for application of novel vaccines or antiviral drugs for prevention or control of EHF and MHF among populations at highest risk for disease

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals

Nitrosocarbonyl Hetero-Diels–Alder Cycloaddition: A New Tool for Conjugation

It is demonstrated that nitrosocarbonyl hetero-Diels-Alder chemistry is an efficient and versatile reaction that can be applied in macromolecular synthesis. Polyethylene glycol functionalized with a hydroxamic acid moiety undergoes facile coupling with cyclopentadiene-terminated polystyrene, through a copper-catalyzed as well as thermal hetero-Diels-Alder reaction. The mild and orthogonal methods used to carry out this reaction make it an attractive method for the synthesis of block copolymers. The resulting block copolymers were analyzed and characterized using GPC and NMR. The product materials could be subjected to thermal retro [4 + 2] cycloaddition, allowing for the liberation of the individual polymer chains and subsequent recycling of the diene-terminated polymers. © 2014 American Chemical Society

Imagination, raisonnement déductif et pensée contrefactuelle chez les enfants de 3 à 5 ans

NANTES-BU Lettres (441092102) / SudocSudocFranceF

Deep variational learning for multiple trajectory prediction of 360° head movements

Prediction of head movements in immersive media is key to design efficient streaming systems able to focus the bandwidth budget on visible areas of the content. Numerous proposals have therefore been made in the recent years to predict 360° images and videos. However, the performance of these models is limited by a main characteristic of the head motion data: its intrinsic uncertainty. In this article, we present an approach to generate multiple plausible futures of head motion in 360° videos, given a common past trajectory. Our method provides likelihood estimates of every predicted trajectory, enabling direct integration in streaming optimization. To the best of our knowledge, this is the first work that considers the problem of multiple head motion prediction for 360° video streaming. We first quantify this uncertainty from the data. We then introduce our discrete variational multiple sequence (DVMS) learning framework, which builds on deep latent variable models. We design a training procedure to obtain a flexible and lightweight stochastic prediction model compatible with sequence-to-sequence recurrent neural architectures. Experimental results on 3 different datasets show that our method DVMS outperforms competitors adapted from the self-driving domain by up to 37% on prediction horizons up to 5 sec., at lower computational and memory costs. Finally, we design a method to estimate the respective likelihoods of the multiple predicted trajectories, by exploiting the stationarity of the distribution of the prediction error over the latent space. Experimental results on 3 datasets show the quality of these estimates, and how they depend on the video category

New considerations for modelling a MED-TVC plant under dynamic conditions

The multiple-effect distillation (MED) technology is nowadays the most promising desalination process to be coupled with variable heat sources, thus leading to a more sustainable way to produce water. In order to prove the potential of this, it is of major interest to develop powerful modelling tools to predict the performance of this coupling. Only a few models have been presented so far. They show promising results but were based on some simplifying assumptions and non-physical constraints that could limit the analysis of the dynamic behaviour of a MED plant. This paper presents new considerations for the dynamic modelling of a MED plant associated with a thermal vapour compression unit, starting from a previous work “A dynamic model for MED-TVC transient operation”. After several improvements, this model is now more representative of the real operating modes of a MED-TVC plant by considering real process inputs. This paper also highlights the importance of accurately modelling the interconnection between effects, the evaporation and condensation processes and the other components, such as the pre-heaters. Here is also presented a control strategy for operating a MED plant under dynamic conditions. Indeed, when a perturbation occurs in the motive steam pressure, it is possible to stabilize the whole plant by a simultaneous variation in the intake seawater mass flow rate at the final condenser. The model has been validated in steady-state conditions with experimental data from a MED-TVC plant operated in Trapani (Sicily) and was used to perform dynamic simulation to prove the feasibility of operating a MED-TVC plant under dynamic conditions, which is a major step toward proving the possibility of a coupling with renewable energies